.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,612,110

« Back to Dashboard

Details for Patent: 7,612,110

Title:Utilization of dialkylfumarates
Abstract: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.
Inventor(s): Joshi; Rajendra Kumar (Zurich, CH), Strebel; Hans-Peter (Muri, CH)
Assignee: Biogen Idec International AG (Zug, CH)
Filing Date:Jun 20, 2007
Application Number:11/765,563
Claims:1. A method of treating autoimmune polyarthritis but not treating psoriatic arthritis, comprising administering, to a patient in need of treatment for said polyarthritis but not for said psoriatic arthritis, an amount of a pharmaceutical preparation effective for treating said polyarthritis, the pharmaceutical preparation comprising at least one excipient or at least one carrier or a combination thereof and an active ingredient only consisting of dimethyl fumarate, methyl hydrogen fumarate, or a combination thereof.

2. The method of claim 1, wherein 10 mg to 300 mg of the active ingredient is administered.

3. The method of claim 1, wherein the active ingredient is provided in one or more capsules.

4. The method of claim 1, wherein the active ingredient consists of 50 mg of dimethyl fumarate.

5. The method of claim 1, wherein the active ingredient consists of 110 mg of dimethyl fumarate.

6. The method of claim 1, wherein the active ingredient consists of 120 mg of dimethyl fumarate.

7. The method of claim 1, wherein the active ingredient consists of methyl hydrogen fumarate.

8. The method of claim 7, wherein the active ingredient consists of 10 mg to 300 mg of methyl hydrogen fumarate.

9. The method of claim 1, wherein the active ingredient consists of dimethyl fumarate.

10. The method of claim 9, wherein the active ingredient consists of 10 mg to 300 mg of dimethyl fumarate.

11. The method of claim 9, wherein the active ingredient consists of 50 mg of dimethyl fumarate.

12. The method of claim 9, wherein the active ingredient consists of 110 mg of dimethyl fumarate.

13. The method of claim 9, wherein the active ingredient consists of 120 mg of dimethyl fumarate.

14. The method of claim 1, wherein the pharmaceutical preparation is formulated for oral administration.

15. The method of claim 1, wherein the pharmaceutical preparation is formulated as a solid dosage form.

16. The method of claim 1, wherein the pharmaceutical preparation is in the form of microtablets.

17. The method of claim 16, wherein the microtablets are provided in one or more capsules, each capsule containing at least 50 mg of dimethyl fumarate.

18. The method of claim 17, wherein each capsule contains at least 110 mg of dimethyl fumarate.

19. The method of claim 18, wherein each capsule contains at least 120 mg of dimethyl fumarate.

20. The method of claim 16, wherein the microtablets are enteric-coated.

21. The method of claim 16, wherein the microtablets have a mean diameter in the range of 0.3 mm to 2.0 mm, exclusive of any coating on the microtablets.

22. The method of claim 21, wherein the microtablets have a mean diameter of 2.0 mm, exclusive of any coating on the microtablets.

23. The method of claim 1, wherein the active ingredient consists of at least 50 mg of dimethyl fumarate.

24. The method of claim 1, wherein the active ingredient consists of at least 110 mg of dimethyl fumarate.

25. The method of claim 1, wherein the active ingredient consists of at least 120 mg of dimethyl fumarate.

26. The method of claim 1, wherein the pharmaceutical preparation comprises at least one carrier.

27. The method of claim 1, wherein the pharmaceutical preparation comprises at least one excipient.

28. The method of claim 1, wherein the active ingredient consists of only both dimethyl fumarate and methyl hydrogen fumarate.

29. The method of claim 1, wherein the pharmaceutical preparation comprises at least one excipient and at least one carrier.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc